Drug class profile · refreshed daily from federal data

Antiarrhythmic

9 molecules in this class, $1.00B combined CY2024 Part D spend across 10.0M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Antiarrhythmic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $1.00Bcombined across class
Total Rx claims: 10.0M3.2M unique beneficiaries
Generic mfrs (active): 86across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Dronedarone

Brand: Multaq · 476K Part D claims (CY24) · 131K beneficiaries · First FDA approval: 2009-07-01

1 generic mfrs 3 plans require PA

Low NADAC$13.19

→

Avg plan cost$13.19

Part D spend $626.9M 1× spread, current vs floor

Class share

63%

of class CY24 spend

View profile →

Amiodarone

Brand: Nexterone · 4.8M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 2001-03-30

15 generic mfrs 0 plans require PA

Low NADAC$0.121

→

Avg plan cost$0.288

Part D spend $116.4M 2× spread, current vs floor

Class share

12%

of class CY24 spend

View profile →

Dofetilide

Brand: Tikosyn · 515K Part D claims (CY24) · 144K beneficiaries · First FDA approval: 1999-10-01

8 generic mfrs 0 plans require PA

Low NADAC$0.188

→

Avg plan cost$0.197

Part D spend $96.7M 1× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Flecainide

2.0M Part D claims (CY24) · 628K beneficiaries · First FDA approval: 2003-01-14

7 generic mfrs

Low NADAC$0.108

→

Avg plan cost$0.174

Part D spend $77.9M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Sotalol

Brand: BETAPACE · 1.7M Part D claims (CY24) · 526K beneficiaries · First FDA approval: 2000-05-04

7 generic mfrs 1 plans require PA

Low NADAC$0.071

→

Avg plan cost$0.172

Part D spend $36.3M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Propafenone

Brand: Propafenone Hydrochloride · 399K Part D claims (CY24) · 123K beneficiaries · First FDA approval: 2000-10-24

10 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.114

→

Avg plan cost$0.362

Part D spend $33.4M 3× spread, current vs floor

Class share

of class CY24 spend

View profile →

Mexiletine

145K Part D claims (CY24) · 44K beneficiaries · First FDA approval: 1995-06-05

8 generic mfrs 0 plans require PA

Low NADAC$0.222

→

Avg plan cost$0.288

Part D spend $14.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lidocaine Hydrochloride

Brand: AKTEN · — Part D claims (CY24) · First FDA approval: 2018-04-18

25 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Procainamide

— Part D claims (CY24) · First FDA approval: 2006-03-08

5 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.